Hoth Therapeutics IncNASDAQ:HOTH
- LAST PRICE1.2300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.1500/ 1
- Ask / Lots1.3200/ 1
- Open / Previous Close0.0000 / 1.2300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HOTH |
|---|---|---|
| 09:32 ET | 678 | 1.2 |
| 09:57 ET | 1387 | 1.1625 |
| 10:01 ET | 2600 | 1.1997 |
| 10:03 ET | 100 | 1.185 |
| 10:10 ET | 119 | 1.17 |
| 10:32 ET | 1507 | 1.16 |
| 10:37 ET | 700 | 1.19 |
| 10:42 ET | 420 | 1.1618 |
| 10:46 ET | 200 | 1.1601 |
| 10:48 ET | 500 | 1.19 |
| 10:50 ET | 2435 | 1.1601 |
| 10:53 ET | 100 | 1.215 |
| 11:06 ET | 100 | 1.18 |
| 11:20 ET | 1727 | 1.15 |
| 11:24 ET | 240 | 1.2 |
| 11:31 ET | 100 | 1.205 |
| 11:40 ET | 100 | 1.16 |
| 12:07 ET | 200 | 1.19 |
| 12:16 ET | 100 | 1.1748 |
| 12:18 ET | 127 | 1.1637 |
| 12:21 ET | 200 | 1.17 |
| 12:43 ET | 100 | 1.18 |
| 01:15 ET | 1000 | 1.1894 |
| 01:24 ET | 100 | 1.18 |
| 01:28 ET | 200 | 1.2 |
| 01:37 ET | 180 | 1.22 |
| 01:42 ET | 100 | 1.2 |
| 01:57 ET | 100 | 1.21 |
| 02:06 ET | 2075 | 1.18 |
| 02:22 ET | 100 | 1.2 |
| 02:24 ET | 118 | 1.1998 |
| 02:31 ET | 100 | 1.17 |
| 02:42 ET | 500 | 1.1737 |
| 03:32 ET | 1494 | 1.22 |
| 03:36 ET | 100 | 1.23 |
Apr 11, 2024
*DJ Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs, from 4:23PM ET on Thursday Apr 11, 2024 by Dow Jones
4:23PM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 5, 2024
DJ Hoth Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co., from 6:25AM ET on Friday Apr 05, 2024 by Dow Jones
6:25AM ET on Friday Apr 05, 2024 by Dow Jones
Apr 2, 2024
DJ Hoth Therapeutics Is Maintained at Buy by EF Hutton, from 9:13AM ET on Tuesday Apr 02, 2024 by Dow Jones
9:13AM ET on Tuesday Apr 02, 2024 by Dow Jones
Mar 27, 2024
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds, from 2:00PM ET on Wednesday Mar 27, 2024 by Dow Jones
2:00PM ET on Wednesday Mar 27, 2024 by Dow JonesHoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment, from 8:27AM ET on Wednesday Mar 27, 2024 by Dow Jones
8:27AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Hoth Therapeutics Inc | 5.4M | -0.5x | --- |
Gold River Productions Inc | 5.1M | 0.0x | --- |
Eastgate Biotech Corp | 5.7M | -1.6x | --- |
GT Biopharma Inc | 5.5M | -0.7x | --- |
Processa Pharmaceuticals Inc | 4.7M | -0.2x | --- |
Vestiage Inc | 5.9M | 12.0x | --- |
Company Information
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.
Contact Information
- Headquarters
- 590 Madison Avenue, 21St FloorNEW YORK, NY, United States 10022
- Phone
- 646-756-2997
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Robb Knie
- Chief Financial Officer
- David Briones
- Independent Director
- Wayne Linsley
- Independent Director
- Jeff Pavell
- Independent Director
- David Sarnoff
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.65 |
EPS | $-2.44 |
Book Value | $2.03 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
